{"analyses":[{"ciLowerLimit":"0.77","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.05","groupDescription":"Kaplan Meier Estimate","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1713","paramType":"Hazard Ratio (HR)","paramValue":"0.90","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"21","upperLimit":"25","value":"22.5"},{"groupId":"OG001","lowerLimit":"22","upperLimit":"26","value":"23.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"409"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Chemotherapy alone until disease progression, unacceptable toxicity, or patient refusal","id":"OG000","title":"Chemotherapy"},{"description":"Chemotherapy and Bevacizumab until disease progression, unacceptable toxicity, or patient refusal","id":"OG001","title":"Chemotherapy + Bevacizumab"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"within approximately 9.6 years","title":"Overall Survival: Months From Time of First Line Therapy","type":"SECONDARY","unitOfMeasure":"months"}